Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4C | Q08493 | 3/20 | 0.53 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10268220 | 0.93 | RPS6KA2 (0.49) | PDE4CRPS6KA2SYKBRD4PTGES | |
| SCHEMBL721634 | 0.92 | RPS6KA2 (0.55) | PDE4CRPS6KA2 | |
| SCHEMBL16845878 | 0.92 | PDE4C (0.46) | PDE4CRPS6KA2SYKALOX5ADORA3 | |
| SCHEMBL723093 | 0.91 | PDE4C (0.55) | PDE4CSYKBRD4PTGESALOX5 | |
| SCHEMBL722271 | 0.91 | PDE4C (0.48) | PDE4CRPS6KA2SYKBRD4PTGES | |
| SCHEMBL15210354 | 0.89 | PDE4C (0.44) | PDE4CRPS6KA2SYKBRD4PTGES | |
| SCHEMBL722839 | 0.86 | PDE4C (0.51) | PDE4CSYKBRD4PTGESALOX5 | |
| SCHEMBL722596 | 0.85 | PDE4C (0.50) | PDE4CSYKBRD4PTGESALOX5 | |
| SCHEMBL723596 | 0.85 | RPS6KA2 (0.60) | PDE4CRPS6KA2SYKADORA3 | |
| SCHEMBL16638609 | 0.85 | PDE4C (0.50) | PDE4CRPS6KA2SYKPTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | PDE4C 2858/4885RPS6KA2 262/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.